Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Bevacizumab-Containing Chemoimmunotherapy for Recurrent Non-Small-Cell Lung Cancer after Chemoradiotherapy: Case Report

Chemoimmunotherapy has become the standard of care as the first-line treatment of advanced or recurrent non-small-cell lung cancer (NSCLC). The bevacizumab-containing chemoimmunotherapy regimen is theoretically more effective than a non-bevacizumab-containing regimen via two mechanisms: a superior o...

Full description

Bibliographic Details
Main Authors: Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Nozomi Tani, Izumi Sato, Mai Tanimura, Takayuki Nakano, Keiko Tanimura, Daishiro Kato, Takayuki Takeda
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Medicina
Subjects:
bevacizumab
chemoimmunotherapy
chemoradiotherapy
non-small-cell lung cancer
recurrence
Online Access:https://www.mdpi.com/1648-9144/57/6/547

Internet

https://www.mdpi.com/1648-9144/57/6/547

Similar Items